探索使用模型开发长效注射剂的支架方法的可行性,以获得监管部门的批准-使用Levonorgestrel的案例研究
Susan Cole1, Henry Pertinez2, Andrew S Butler1
1Medicines and Healthcare Products Regulatory Agency, Canary Wharf, London E14 4PU, UK.
Pharmaceuticals (Basel, Switzerland)
|January 8, 2025
概括
使用levonorgestrel的新型长效可逆避孕药 (LARC) 的分类方法有希望,但需要更多的安全数据. 当前的法规可能允许减少应用程序的进一步证据,可能使用现实世界的数据和建模.
科学领域:
- 药理学和生殖健康
- 药物开发和监管科学 药物开发和监管科学
背景情况:
- 长效可逆避孕药 (LARCs) 的开发至关重要.
- 使用临床数据的分类方法可以通过将药物暴露与疗效和安全度范围相匹配来简化LARC开发.
- 这种方法旨在减少LARC新产品的时间和成本.
研究的目的:
- 评估支持新型莱沃诺格斯特雷尔LARC的分类方法的现有数据.
- 为了确定这种方法是否可以结论一个新的levonorgestrel产品的可比效果和安全性.
主要方法:
- 使用三种LARC产品的珍珠指数数据来建模levonorgestrel疗效,以估计最小有效度.
- 审查了文献,以确定产品安全的最大度.
- 检查了欧洲和英国的监管数据库,以确定分类方法的优先权.
主要成果:
- 定义了最小有效的勒沃诺格斯特勒度 (200-400 pg/mL).
- 最大安全度的定义不太清楚.
- 监管指南支持分类方法,但仅基于药理动力学数据的许可具有有限的优先权.
结论:
- 目前对暴露-反应的理解不足以实现莱沃诺格斯特勒LARC分类方法.
- 额外的安全数据可以减少监管应用程序包.
- 未来的工作应该整合现实世界的数据和系统建模来支持这种方法.
相关概念视频
One-Compartment Open Model for IV Bolus Administration: General Considerations
156
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
156
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
194
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
194
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
43
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
43
Biopharmaceutics and Pharmacokinetics: Overview
1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K


